Association of MTR A2756G Gene Polymorphism with Risk of Head and Neck Cancer
MTR A2756G Gene Polymorphism and HNC
Abstract
Objective: To perform genotyping for MTR A2756G polymorphism and identification of risk factors associated with head and neck squamous cell carcinoma (HNSCC).
Study Design: Cross section, comparative study.
Place and Duration of Study: The study was carried out at the Department of Biochemistry of Quaid-i- Azam University, Islamabad from October 2014 to August 2015.
Materials and Methods: In this study, 292 diagnosed patients HNSCC and 324 normal individuals without any history of cancer were enrolled. Blood samples of patients and controls were collected in ethylenediamine tetra acetic acid (EDTA) and DNA was extracted using conventional method. All samples were genotyped for the MTR A2756G polymorphism using PCR-RFLP. Frequency of polymorphism was compared between HNSCC patients andcontrols. MultipleLogisticRegression(MLR)andchi-squaretestwasperformedtoexaminetheassociation of MTR A2756G polymorphism with risk factor.
Results: Chi-square test of independence showed statistically significant difference among the variables of age, smoking and MTR A2756G genotype (p-value<0.05). Multivariate analysis showed that smoking (adjusted OR, 3.7; 95% CI, 2.3 – 6.0), age groups 41 – 50 years (adjusted OR, 3.6; 95% CI, .9 – 6.7) and > 60 years (adjusted OR, 3.5; 95% CI, 1.7 – 7.3), MTR 2756 AG genotype (adjusted OR, 2.1; 95% CI, 1.3 – 3.5) is associated with increased risk of HNSCC.
Conclusion: The results suggest that the genetic polymorphism MTR A2756G is associated with the occurrence of HNSCC in the Pakistani population while the individuals between 40 to 50 years of age and those who are smokers are at a greater risk of developing HNSCC.
References
Marur S, D'Souza G, Westra WH, Forastiere AA. HPV- associated head and neck cancer: a virus-related cancer epidemic. The lancet oncology. 2010; 11: 781-9.
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA: a cancer journal for clinicians. 2010; 60: 277-300.
Society AC. Cancer Facts & Figures 2013.
Hanif M, Zaidi P, Kamal S, Hameed A. Institution-based cancer incidence in a local population in Pakistan: nine year data analysis. Asian Pac J Cancer Prev. 2009; 10: 227-230.
Abusail MS, Dirweesh AMA, Awad R, Salih A, Gadelkarim AH. Expression of EGFR and p53 in Head and Neck Tumors among Sudanese Patients. Asian Pacific Journal of Cancer Prevention. 2013; 14: 6415-8.
Kane MA. The role of folates in squamous cell carcinoma of the head and neck. Cancer detection and prevention. 2005; 29: 46-53.
Marcu LG, Yeoh E. A review of risk factors and genetic alterations in head and neck carcinogenesis and
implications for current and future approaches to treatment. Journal of cancer research and clinical oncology.
; 135: 1303-14.
Pelucchi C, Talamini R, Negri E, Levi F, Conti E, Franceschi S, et al. Folate intake and risk of oral and pharyngeal cancer. Annals of Oncology. 2003; 14: 1677-81.
Mishra A, Meherotra R. Head and Neck Cancer: Global Burden and Regional Trends in India. Asian Pacific Journal of Cancer Prevention. 2014; 15: 537-50.
D'Alessio AC, Szyf M. Epigenetic tête-à-tête: the bilateral relationship between chromatin modifications and DNA methylation This paper is one of a selection of papers published in this Special Issue, entitled 27th International West Coast Chromatin and Chromosome Conference, and has undergone the Journal's usual peer review process. Biochemistry and cell biology. 2006; 84: 463-6.
Niculescu MD, Zeisel SH. Diet, methyl donors and DNA methylation: interactions between dietary folate, methionine and choline. The Journal of nutrition. 2002; 132: 2333S-5S.
Pufulete M, Al-Ghnaniem R, Leather AJ, Appleby P, Gout S, Terry C, et al. Folate status, genomic DNA hypomethylation, and risk of colorectal adenoma and cancer: a case control study. Gastroenterology. 2003; 124: 1240-8.
Ehrlich M. The ICF syndrome, a DNA methyltransferase 3B deficiency and immunodeficiency disease. Clinical immunology. 2003; 109: 17-28.
Ren DN, Kim IY, Koh SB, Chang SJ, Eom M, Yi SY, et al. Comparative analysis of thymidylate synthase at the protein, mRNA, and DNA levels as prognostic markers in colorectal adenocarcinoma. Journal of surgical oncology. 2009; 100: 546-52.
Banerjee RV, Matthews RG. Cobalamin-dependent methionine synthase. The FASEB journal. 1990; 4: 1450-9.
Leclerc D, Campeau E, Goyette P, Adjalla CE, Christensen B, Ross M, et al. Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. Human molecular genetics. 1996; 5: 1867-74.
Sharp L, Little J. Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: a HuGE review. American journal of epidemiology. 2004; 159: 423-43.
Fredriksen Å, Meyer K, Ueland PM, Vollset SE, Grotmol T, Schneede J. Large-scale population-based metabolic phenotyping of thirteen genetic polymorphisms related to one-carbon metabolism. Human mutation. 2007; 28: 856-65
Lissowska J, Gaudet MM, Brinton LA, Chanock SJ, Peplonska B, Welch R, et al. Genetic polymorphisms in the one-carbon metabolism pathway and breast cancer risk: A population-based case–control study and meta-analyses. International journal of cancer. 2007; 120: 2696-2703.
Chen K, Song L, Jin MJ, Fan CH, Jiang QT, Yu WP. Association between genetic polymorphisms in folate metabolic enzyme genes and colorectal cancer: a nested case-control study. Zhonghua zhong liu za zhi Chinese journal of oncology. 2006; 28: 429-32.
Shi Q, Zhang Z, Li G, Pillow PC, Hernandez LM, Spitz MR, et al. Polymorphisms of methionine synthase and methionine synthase reductase and risk of lung cancer: a case-control analysis. Pharmacogenetics and genomics. 2005; 15: 547-55
Sarbia M, Stahl M, Von Weyhern C, Weirich G, Pühringer- Oppermann F. The prognostic significance of genetic polymorphisms (Methylenetetrahydrofolate Reductase C677T, Methionine Synthase A2756G, Thymidilate Synthase tandem repeat polymorphism) in multimodally treated oesophageal squamous cell carcinoma. British journal of cancer. 2005; 94: 203-7.
Galbiatti AL, Ruiz MT, Biselli-Chicote PM, Raposo LS, Maniglia JV, Pavarino-Bertelli EC, et al. 5 Methyltetrahydrofolate-homocysteine methyltransferase gene polymorphism (MTR) and risk of head and neck cancer. Brazilian Journal of Medical and Biological Research. 2010; 43: 445-50.
Zhang FF, Terry MB, Hou L, Chen J, Lissowska J, Yeager M, et al. Genetic polymorphisms in folate metabolism and the risk of stomach cancer. Cancer Epidemiology Biomarkers & Prevention. 2007; 16: 115-21.
Kruszyna Ł, Lianeri M, Rydzanicz M, Gajęcka M, Szyfter K, Jagodziński PP, et al. Polymorphic variants of folate metabolism genes and the risk of laryngeal cancer. Molecular biology reports. 2010; 37: 241-7.
Suzuki T, Matsuo K, Hasegawa Y, Hiraki A, Wakai K, Hirose K, et al. One-carbon metabolism-related gene polymorphisms and risk of head and neck squamous cell carcinoma: Case–control study. Cancer science. 2007; 98: 1439-46.
Ahmed I, Islam M, Arshad W, Mannan A, Ahmad W, Mirza B. High-quality plant DNA extraction for PCR: an easy approach. Journal of applied genetics. 2009; 50: 105-7.
Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. The Lancet. 2008; 371: 1695-1709.
Lung T, TĂŞCĂU OC, ALMĂŞAN HA, MUREŞAN O. Head and neck cancer, epidemiology and histological aspects–Part 1: A decade's results 1993–2002. Journal of Cranio- Maxillofacial Surgery. 2007; 35: 120-5.
Abdulamir AS, Hafidh RR, Abdulmuhaimen N, Abubakar F, Abbas KA. The distinctive profile of risk factors of nasopharyngeal carcinoma in comparison with other head and neck cancer types. BMC public health. 2008; 8: 400.
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA: a cancer journal for clinicians. 2005; 55: 74-108.
Llewellyn C, Johnson NW, Warnakulasuriya K. Risk factors for oral cancer in newly diagnosed patients aged 45 years and younger: a case–control study in Southern England. Journal of oral pathology & medicine. 2004; 33: 525-32.
Chen PH, Shieh TY, Ho PS, Tsai CC, Yang YH, Lin YC, et al. Prognostic factors associated with the survival of oral and pharyngeal carcinoma in Taiwan. BMC cancer. 2007; 7: 101.
Tai J, Yang M,Ni X, Yu D, Fang J, Tan W, etal. Genetic polymorphisms in cytochrome P450 genes are associated with an increased risk of squamous cell carcinoma of the larynx and hypopharynx in a Chinese population. Cancer genetics and cytogenetics. 2010; 196: 76-82.
Almadori G, Bussu F, Galli J, Cadoni G, Zappacosta B, Persichilli S, et al. Serum folate and homocysteine levels in head and neck squamous cell carcinoma. Cancer. 2002; 94: 1006-11.
Raval GN, Sainger RN, Rawal RM, Patel JB, Patel BP, Jha FP, et al. Vitamin B. Asian Pacific Journal of Cancer Prevention. 2002; 3: 155-62.
Chen LH, Liu ML, Hwang HY, Chen LS, Korenberg J, Shane B, et al. Human methionine synthase cDNA cloning, gene localization, and expression. Journal of Biological Chemistry. 1997; 272: 3628-34
Scott JM, editor Genetic Variation of Homocysteine Metabolism and Atherosclerosis. Nestle Nutrition Workshop Series; 2003; pp: 1-24 : Philadelphia; Lippincott- Raven; 1999.
Dekou V, Gudnason V, Hawe E, Miller GJ, Stansbie D, Humphries SE, et al. Gene-environment and gene-gene interaction in the determination of plasma homocysteine levels in healthy middle-aged men. THROMBOSIS AND HAEMOSTASIS-STUTTGART. 2001; 85: 67-74.
Harmon DL, Shields DC, Woodside JV, McMaster D, Yarnell JW, Young IS, et al. Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations. Genetic epidemiology. 1999; 17: 298-309.
Li YN, Gulati S, Baker PJ, Brody LC, Banerjee R, Kruger WD. Cloning, mapping and RNA analysis of the human methionine synthase gene. Human molecular genetics. 1996; 5: 1851-8.
Ma J, Stampfer MJ, Christensen B, Giovannucci E, Hunter DJ, Chen J, et al. A polymorphism of the methionine synthase gene: association with plasma folate, vitamin B12, homocyst (e) ine, and colorectal cancer risk. Cancer Epidemiology Biomarkers & Prevention. 1999; 8: 825-9.
Silaste ML, Rantala M, Sampi M, Alfthan G, Aro A, Kesäniemi YA. Polymorphisms of key enzymes in homocysteine metabolism affect diet responsiveness of plasma homocysteine in healthy women. The Journal of nutrition. 2001; 131: 2643-7.
Paz MF, Avila S, Fraga MF, Pollan M, Capella G, Peinado MA, et al. Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors. Cancer research. 2002; 62: 4519- 24.
De Capoa A, Musolino A, Della Rosa S, Caiafa P, Mariani L, Del Nonno F, et al. DNA demethylation is directly related to tumour progression: evidence in normal, pre-malignant and malignant cells from uterine cervix samples. Oncology reports. 2003; 10: 545-9.
Brothman AR, Swanson G, Maxwell TM, Cui J, Murphy KJ, Herrick J, et al. Global hypomethylation is common in prostate cancer cells: a quantitative predictor for clinical outcome? Cancer genetics and cytogenetics. 2005; 156: 31- 6.
Ma J, Stampfer MJ, Christensen B, Giovannucci E, Hunter DJ, Chen J, et al. A polymorphism of the methionine synthase gene: association with plasma folate, vitamin B12, homocyst (e) ine, and colorectal cancer risk. Cancer Epidemiology Biomarkers & Prevention. 1999; 8: 825-9.
Silaste ML, Rantala M, Sampi M, Alfthan G, Aro A, Kesäniemi YA. Polymorphisms of key enzymes in homocysteine metabolism affect diet responsiveness of plasma homocysteine in healthy women. The Journal of nutrition. 2001; 131: 2643-7.
Paz MF, Avila S, Fraga MF, Pollan M, Capella G, Peinado MA, et al. Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors. Cancer research. 2002; 62: 4519- 24.
De Capoa A, Musolino A, Della Rosa S, Caiafa P, Mariani L, Del Nonno F, et al. DNA demethylation is directly related to tumour progression: evidence in normal, pre-malignant and malignant cells from uterine cervix samples. Oncology reports. 2003; 10: 545-9.
Brothman AR, Swanson G, Maxwell TM, Cui J, Murphy KJ, Herrick J, et al. Global hypomethylation is common in prostate cancer cells: a quantitative predictor for clinical outcome? Cancer genetics and cytogenetics. 2005; 156: 31- 6.
